The single-cell analysis market size in the Middle East and Africa was valued at USD 0.21 billion in 2022 and is estimated to be growing at a CAGR of 16.02% to reach USD 0.44 billion by 2027.
Increasing advancements in technology, growth in the biotechnology and biopharmaceutical industries, and extensive applications of single-cell analysis in cancer research are expected to propel the market growth in this region during the forecast period. Increasing funds and investments from the government and other organizations are likely to fuel the growth. In addition, rising standard increases, and a high occurrence rate of infectious and chronic diseases and neurological disorders foster the market. According to the Cancer Government, around 1.8 million people were diagnosed with cancer by the end of 2019, as of an increase in cancer as there is a considerable need for analysis of cancer cells, which surge the market growth throughout the review period. In addition, the government took increasing per capita income and steps to empower and strengthen the research and development activities towards the healthcare domain, which propels the market.
The expensive nature of single-cell analysis products is to impede the market growth over the analysis period. Limited healthcare reimbursement policies and guidelines and also and affairs relevant to intellectual property hamper the market growth. Besides these, strict regulations for the approval of the new drug discovery and therapeutics and new products hinder the market. There is massive competition in the market amidst already existing and the latest entries, which restrain the single-cell analysis market throughout the analysis period.
This research report on the Middle East and Africa single-cell analysis market has been segmented and sub-segmented into the following categories:
Regionally, Middle East & Africa is regarded to have a moderate share in the global market during the forecast period and are primarily driven by the enhancement of advanced therapeutics for cancer treatment. UAE and South Africa are the two major contributors to the market growth in this region.
The UAE single-cell analysis market is expected to register the most massive share in the MEA market during the period, increasing attention towards personalized medicine and advancements in technologies for the single-cell analysis market, which fuels the market.
Following UAE, the South African market is predicted to showcase a healthy CAGR during the forecast period. South Africa is the introduction of new single-cell genomic centers for many years projected to boost the market. Other countries like Saudi Arabia, Nigeria, Egypt, Ethiopia, and the rest of the MEA are expected to have notable growth in single-cell analysis during the forecast period.
KEY MARKET PLAYERS:
Merck KGaA, Becton, Dickinson and Company, Promega Corporation, Danaher Corporation, General ElectricCompany, Thermo Fisher Scientific, Miltenyi Biotec, Illumina, Bio-Rad Laboratories, Fluidigm Corporation, NanoString Technologies, Agilent Technologies, Abcam Plc, NuGEN Technologies Inc., LumaCyte, PluriSelect Life Science UG & Co. KG, Sysmex Partec, Bio-Techne Corporation, Promega Corporation, 10x Genomics, WaferGen Bio-systems, Bruker, and Fluxion Bioscience are some of the leading companies in the MEA single-cell analysis market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com